Impact of COVID-19 Pandemic in Antibiotic Consumption in Navarre (Spain): An Interrupted Time Series Analysis

Author:

Alzueta Natalia12ORCID,Echeverría Amaya23,García Patricia23ORCID,Sanz Lorea23,Gil-Setas Alberto24,Beristain Xabier24,Aldaz Pablo25,Garjón Javier23ORCID

Affiliation:

1. Hospital Reina Sofía, Navarre Health Service, 31500 Tudela, Spain

2. IdiSNA, Health Research Institute of Navarre, 31008 Pamplona, Spain

3. Subdirectorate of Pharmacy, Navarre Health Service, 31002 Pamplona, Spain

4. Clinical Microbiology Department, Hospital Universitario de Navarra, Navarre Health Service, 31008 Pamplona, Spain

5. San Juan Primary Care Center, Navarre Health Service, 31011 Pamplona, Spain

Abstract

On 11 March 2020, the World Health Organization declared coronavirus disease 19 (COVID-19) a global pandemic. This exceptional situation changed the world not only in terms of mortality and morbidity, but also in terms of epidemiology and health system resources consumption. The objective of this work was to analyze the consumption of antibiotics during the period around the pandemic in our region. A drug utilization study was performed comparing the antibiotic consumption in the community during the years 2018, 2019, 2020, and 2021. Quarterly antibiotic use (defined daily doses (DDD) per 1000 inhabitants per day (DID)) and number of patients treated were the outcomes. Interrupted time series regression analysis was performed to estimate the statistical significance of the change in level of consumption before and after the COVID-19 pandemic. The drop of global antibiotic consumption was statistically significant, both in number of patients and in DID when analyzing pre-pandemic period versus pandemic period. The use of strategic antibiotics for respiratory infections such as amoxicillin, amoxicillin-clavulanic acid, and levofloxacin also decreased significantly. Seasonal pattern of use of antibiotics disappeared due to the global measures imposed over the world to work against COVID-19.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Reference30 articles.

1. Antibiotic Resistance: One Health One World Outlook;Aslam;Front. Cell. Infect. Microbiol.,2021

2. (2022, November 11). Join Action Antimicrobial Resistance and Healthcare-Associated Infections. (EU JAMRAI). Available online: https://eu-jamrai.eu/.

3. Ministerio de Sanidad Consumo y Bienestar Social (2022, November 11). Plan Nacional Frente a las Resistencias Antibióticos (PRAN). Programas de Optimización de Uso de Antibióticos (PROA). Available online: https://www.resistenciaantibioticos.es.

4. Prudent use of antibiotics and suggestions for improvement in the primary health care system;Llor;Enferm. Infecc. Microbiol. Clin.,2010

5. Appropriateness of antibiotic prescribing in a primary care area: A cross-sectional study;Enferm. Infecc. Microbiol. Clin.,2014

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3